We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-7.93%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$973M
AUM Growth
-$259M
Cap. Flow
-$139M
Cap. Flow %
-14.32%
Top 10 Hldgs %
31.9%
Holding
97
New
2
Increased
29
Reduced
54
Closed
5

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$13.3M
2
CI icon
Cigna
CI
+$11.7M
3
BIIB icon
Biogen
BIIB
+$9.55M
4
HUM icon
Humana
HUM
+$6.5M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$6.19M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$15.7M
2
BDX icon
Becton Dickinson
BDX
+$14.9M
3
HCA icon
HCA Healthcare
HCA
+$14.6M
4
BSX icon
Boston Scientific
BSX
+$12.9M
5
COO icon
Cooper Companies
COO
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DHR icon
26
Danaher
DHR
$147B
$14.7M 1.51%
63,952
-19,350
-23% -$4.76M
ABT icon
27
Abbott
ABT
$188B
$14.5M 1.49%
128,000
-7,000
-5% -$809K
HUM icon
28
Humana
HUM
$46.3B
$14M 1.44%
55,230
+24,230
+78% +$6.5M
NBIX icon
29
Neurocrine Biosciences
NBIX
$16.8B
$13.7M 1.41%
100,317
+28,567
+40% +$3.53M
ZBH icon
30
Zimmer Biomet
ZBH
$18.7B
$13.1M 1.35%
+124,000
New +$13.3M
COR icon
31
Cencora
COR
$62B
$12.1M 1.24%
53,750
+8,600
+19% +$2.02M
CVS icon
32
CVS Health
CVS
$122B
$12M 1.23%
267,500
+83,500
+45% +$4.68M
CNC icon
33
Centene
CNC
$32.9B
$11.8M 1.22%
195,482
+78,500
+67% +$4.9M
BDX icon
34
Becton Dickinson
BDX
$48.9B
$10.9M 1.12%
47,900
-64,600
-57% -$14.9M
DVAX
35
DELISTED
Dynavax Technologies
DVAX
$10.7M 1.1%
839,131
-350,869
-29% -$4.24M
COO icon
36
Cooper Companies
COO
$14.9B
$10.6M 1.09%
115,000
-113,000
-50% -$11.5M
AXSM icon
37
Axsome Therapeutics
AXSM
$11.4B
$10.4M 1.07%
122,600
– –
HCA icon
38
HCA Healthcare
HCA
$89.6B
$10.3M 1.06%
34,379
-41,850
-55% -$14.6M
MOH icon
39
Molina Healthcare
MOH
$10.4B
$9.95M 1.02%
34,200
+4,600
+16% +$1.42M
IOVA icon
40
Iovance Biotherapeutics
IOVA
$2.9B
$9.14M 0.94%
1,235,448
+182,948
+17% +$1.7M
JANX icon
41
Janux Therapeutics
JANX
$1B
$9.1M 0.94%
170,000
+63,153
+59% +$3.34M
ALGN icon
42
Align Technology
ALGN
$12.5B
$8.74M 0.9%
41,900
-13,100
-24% -$2.93M
ELV icon
43
Elevance Health
ELV
$86.2B
$8.54M 0.88%
23,150
-27,350
-54% -$11.4M
TMO icon
44
Thermo Fisher Scientific
TMO
$222B
$8.14M 0.84%
15,640
-9,460
-38% -$5.2M
SYK icon
45
Stryker
SYK
$133B
$8.1M 0.83%
22,500
-500
-2% -$185K
TGTX icon
46
TG Therapeutics
TGTX
$7.52B
$7.9M 0.81%
262,500
+91,000
+53% +$2.61M
IONS icon
47
Ionis Pharmaceuticals
IONS
$9.46B
$7.43M 0.76%
212,500
+17,500
+9% +$654K
CYTK icon
48
Cytokinetics
CYTK
$10.5B
$7.02M 0.72%
149,250
-31,250
-17% -$1.62M
APLS
49
DELISTED
Apellis Pharmaceuticals
APLS
$6.24M 0.64%
195,591
-171,909
-47% -$5.17M
BNTX icon
50
BioNTech
BNTX
$23.3B
$6.01M 0.62%
52,750
+1,750
+3% +$200K
1
2
3 4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Rhenman & Partners Asset Management held 97 positions worth $973M, down 21% from $1.23B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $139M in Q4 2024, closing 5 positions and reducing 54 holdings. Its most notable exit was Evolent Health, an estimated $7.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Zimmer Biomet worth $13.1M.

  • Rhenman & Partners Asset Management's largest Q4 2024 buy was Zimmer Biomet: 124,000 shares worth $13.1M.
  • Rhenman & Partners Asset Management added most to Cigna in Q4 2024, an estimated $11.7M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2024 reduction was Natera, cutting an estimated $15.7M.
  • Rhenman & Partners Asset Management fully exited Evolent Health in Q4 2024, selling an estimated $7.49M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 32% of its $973M portfolio in Q4 2024.
  • Rhenman & Partners Asset Management opened 2 new positions and closed 5 in Q4 2024.
  • Rhenman & Partners Asset Management's portfolio value fell 21% quarter-over-quarter to $973M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2024, filed 13 Feb 2025.